Agios Pharmaceuticals Beats Q3 2026 Estimates as Revenue Rises 330% to $55.4M

Agios Pharmaceuticals (AGIO) beat estimates for the third quarter of 2026 on both revenue and adjusted EPS. Revenue was $55.4 million, up 330% from a year earlier, above the $51.6 million estimate, and adjusted EPS was -$1.09, up 39% from a year earlier, above the -$1.24 estimate.

Shares fell 0.3% in premarket trading as of 6:30 a.m. ET, to $31.30 from a $31.38 close.

Q3 2026 scorecard

By our calculation, revenue was $3.7 million above the estimate and adjusted EPS was $0.15 above it. The QoQ column compares with the previous quarter's revenue of $44.7 million and adjusted EPS of -$1.69. The YoY column compares with $12.9 million and -$1.78 in the same quarter a year earlier.

Track record

• EPS record. Adjusted EPS beat the estimate in 5 of the last 8 reports, including this one.
• Revenue record. Revenue beat the estimate in 7 of the last 8 reports.
• Revenue trend. Revenue over the last 5 reports, oldest first: $12.9 million, $20.0 million, $20.7 million, $44.7 million and $55.4 million.

What to watch

• Next-quarter estimates. Consensus calls for EPS of -$1.15 and revenue of $59.6 million next quarter, based on 7 analysts.
• Revenue growth. Whether revenue keeps growing from a year earlier after this quarter's 330% increase to $55.4 million.
• Estimate record. Whether Agios Pharmaceuticals extends a record of beating EPS estimates in 5 of its last 8 reports.
• Related coverage. See our reports on NCR Voyix, Vontier, Teleflex and Strategic Education.

Sources: Results are from Agios Pharmaceuticals's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Agios Pharmaceuticals's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.